On Thursday shares of Facebook, Inc. (NASDAQ:FB) closed at $82.31. Company’s sales growth for last 5 years was 74.20% and EPS growth for next 5 years is recorded as 31.02%. Facebook, Inc. (NASDAQ:FB) said that, it is to appeal a ruling that it must pay £20,000 in damages to a convicted child abuser who featured on its site.
XBiotech Inc (NASDAQ:XBIT) in last trading activity decreased -2.32% to close at $22.71. XBiotech Inc (NASDAQ:XBIT) is -10.45% away from its 52 week high. On 15 April, XBiotech Inc (NASDAQ:XBIT) said that, it has taken its mission to develop drugs from naturally occurring monoclonal antibodies to the public markets. The company sold 4 million shares at $19 a piece, in the middle of its expected range, to raise $76 million.
On Thursday shares of Galena Biopharma, Inc. (NASDAQ:GALE) closed at $1.43.
Galena Biopharma, Inc. (NASDAQ:GALE) announced the completion of enrollment in the NeuVax™ (nelipepimut-S) Phase 3 PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial.
McCormick & Company, Incorporated (NYSE:MKC) has 0.10% insider ownership while its institutional ownership stands at 86.10%. In last trading activity company’s stock closed at $77.48. McCormick & Company, Incorporated (NYSE:MKC) announced that Cecile K. (Cile) Perich, Senior Vice President & Chief Human Relations Officer, will retire effective June 1, 2015.
On last trading day Omnicom Group Inc. (NYSE:OMC) remains unchanged to close at $77.39. Its volatility for the week is 1.19% while volatility for the month is 1.21%. OMC’s sales growth for past 5 years was 5.50% and its EPS growth for past 5 years was 11.30%. Omnicom Group Inc. (NYSE:OMC) monthly performance is 0.32%. Omnicom Group Inc. (NYSE:OMC) was downgraded by Pivotal Research from a “hold” rating to a “sell” rating in a research note issued on Monday. They currently have a $66.00 target price on the stock, down from their previous target price of $71.00. Pivotal Research’s price target would indicate a potential downside of 15.33% from the company’s current price.